StockData

Intercure Ltd. (INCR) stock

INCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026Score 3/30
$3.98+0.07 (+1.79%)

Close on Nov 12, 2026Market cap $217.63MP/E –Yield –

Intercure Ltd. grew revenue 13.1% to 270.20M ILS over fiscal 2025. Free cash flow was 13.29M ILS. At the latest close the market valued the company at 698.76M ILS.

Revenue
270.20M ILS
+13.1% vs. a year earlier
Operating income
-27.24M ILS
FY2025
Free cash flow
13.29M ILS
FY2025
EPS, diluted
-0.66 ILS
FY2025

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025

Valuation

Market cap
698.76M ILS
P/E ratio
–
Price to sales
2.59
Price to book
1.76
Dividend yield
–
Free cash flow yield
1.90%

Fundamentals

Revenue
270.20M ILS
Net income
-35.71M ILS
EPS, diluted
-0.66 ILS
Free cash flow
13.29M ILS

Trading

Previous close
$3.91
Open
$3.84
Day's range
$3.73 – $3.98
Volume
7,231
Average volume (20 days)
12,341
Beta (5 years)
0.90
RSI (14 days)
44.1
Volatility (1 year)
69.4%
Relative volume
0.39×
WACC
8.7%

Market cap history

Month-end market cap since 2020, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

PeriodINCRS&P 500DifferenceINCR per yearS&P 500 per year
1 month-19.6%-2.7%−16.9 pts
3 months-17.5%-1.7%−15.7 pts
Year to date-12.5%+11.9%−24.4 pts
1 year-41.5%+12.0%−53.5 pts
3 years-25.6%+78.2%−103.8 pts-9.4%+21.2%
5 years-90.8%+73.2%−164.0 pts-38.0%+11.6%

Eight years at a glance

Fiscal years 2018 to 2025, ILS

Revenue

270.20M ILS+13.1% YoY

Gross profit

33.18M ILS+9.8% YoY

Operating income

-27.24M ILS

Net income

-35.71M ILS

EPS, diluted

-0.66 ILS

Free cash flow

13.29M ILS
Reported period

Press releases

Releases Intercure filed with the SEC as exhibits to Form 8-K or 6-K

  1. Regains Compliance with Nasdaq Minimum Bid Price Requirement
    6-K
  2. Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
    6-K
  3. GENERAL MEETING OF SHAREHOLDERS TO BE
    6-K
  4. FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 12, 2026
    6-K
  5. InterCure Secures NIS 22 Million in Private Placement
    6-K
  6. Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial
    6-K
All press releases and earnings

About Intercure

Pharmaceutical Preparations

InterCure Ltd. is an Israel-based company operating primarily within the cannabis and biomed segments. The company engages in the research, production, manufacturing, distribution, export, and import of pharmaceutical-grade medical cannabis and cannabis-based medical products. Through its cultivation sites and commercial channels, InterCure supplies and distributes products to medical patients, pharmacies, and external distribution partners across regulated markets.

Company profile, executives and history

Intercure stock: common questions

What is Intercure's stock price?

INCR closed at $3.98 on Nov 12, 2026, up 1.79% on the day.

What is Intercure's market cap?

Intercure was worth $217.63M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.

What is INCR's P/E ratio?

Intercure lost money over fiscal 2025 (diluted EPS -0.66 ILS), so it has no meaningful P/E ratio.

How much revenue does Intercure make?

Intercure reported revenue of 270.20M ILS for fiscal 2025, up 13.1% from a year earlier.

Does Intercure pay a dividend?

No. Intercure has not paid a cash dividend over the last twelve months.

How has INCR stock performed over the past year?

Including dividends, INCR returned -41.5% over the past year, against +12.0% for the S&P 500.

Who are Intercure's competitors?

Companies most similar to Intercure by business, industry and size include OGI, KMDA, IMCC, ACB, VREOF.

See a number that looks wrong?